Interactions between androgen receptor signaling and other molecular pathways in prostate cancer progression: Current and future clinical implications
出版年份 2020 全文链接
标题
Interactions between androgen receptor signaling and other molecular pathways in prostate cancer progression: Current and future clinical implications
作者
关键词
Prostate cancer, CRPC, Resistance mechanisms, Androgen receptor, DNA repair, PI3K
出版物
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
Volume 157, Issue -, Pages 103185
出版商
Elsevier BV
发表日期
2020-11-28
DOI
10.1016/j.critrevonc.2020.103185
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- IL-23 and PSMA-targeted duo-CAR T cells in Prostate Cancer Eradication in a preclinical model
- (2020) Dawei Wang et al. Journal of Translational Medicine
- Cancer statistics, 2019
- (2019) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- CART cell therapy for prostate cancer: status and promise
- (2019) Haiyuan Yu et al. OncoTargets and Therapy
- ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer
- (2019) Andrew J. Armstrong et al. JOURNAL OF CLINICAL ONCOLOGY
- Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer
- (2019) Ian D. Davis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer
- (2019) Kim N. Chi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012
- (2018) Maha Hussain et al. JOURNAL OF CLINICAL ONCOLOGY
- Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial
- (2018) Noel Clarke et al. LANCET ONCOLOGY
- KEYNOTE-199: Pembrolizumab (pembro) for docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC).
- (2018) Johann S. De Bono et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of Radium-223 in Bone-metastatic Castration-resistant Prostate Cancer with and Without Homologous Repair Gene Defects
- (2018) Pedro Isaacsson Velho et al. EUROPEAN UROLOGY
- Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer
- (2017) Andrew J. Armstrong et al. EUROPEAN JOURNAL OF CANCER
- Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study
- (2017) Tomasz M. Beer et al. EUROPEAN UROLOGY
- Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer
- (2017) Tomasz M. Beer et al. JOURNAL OF CLINICAL ONCOLOGY
- Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis
- (2017) Samra Turajlic et al. LANCET ONCOLOGY
- WNT signalling in prostate cancer
- (2017) Virginia Murillo-Garzón et al. Nature Reviews Urology
- Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
- (2017) Karim Fizazi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
- (2017) Nicholas D. James et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Phase I Study of Abiraterone Acetate Combined with BEZ235, a Dual PI3K/mTOR Inhibitor, in Metastatic Castration Resistant Prostate Cancer
- (2017) Xiao X. Wei et al. ONCOLOGIST
- SOX2 promotes lineage plasticity and antiandrogen resistance in TP53 - and RB1 -deficient prostate cancer
- (2017) Ping Mu et al. SCIENCE
- Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance
- (2017) Sheng Yu Ku et al. SCIENCE
- Transdifferentiation as a Mechanism of Treatment Resistance in a Mouse Model of Castration-Resistant Prostate Cancer
- (2017) Min Zou et al. Cancer Discovery
- Treatment strategies for DNA repair-deficient prostate cancer
- (2017) Benjamin A. Teply et al. Expert Review of Clinical Pharmacology
- Co-stimulatory signaling determines tumor antigen sensitivity and persistence of CAR T cells targeting PSCA+ metastatic prostate cancer
- (2017) Saul J. Priceman et al. OncoImmunology
- Pembrolizumab for patients with advanced prostate adenocarcinoma: Preliminary results from the KEYNOTE-028 study
- (2016) A. Hansen et al. ANNALS OF ONCOLOGY
- Coinhibitory Pathways in Immunotherapy for Cancer
- (2016) Susanne H. Baumeister et al. Annual Review of Immunology
- Open-label, multicenter, phase 1 study of alisertib (MLN8237), an aurora A kinase inhibitor, with docetaxel in patients with solid tumors
- (2016) Julie N. Graff et al. CANCER
- A phase 2 clinical trial of everolimus plus bicalutamide for castration-resistant prostate cancer
- (2016) Helen Chow et al. CANCER
- N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer
- (2016) Etienne Dardenne et al. CANCER CELL
- N-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial Cells
- (2016) John K. Lee et al. CANCER CELL
- The Emerging Role of B Cells in Tumor Immunity
- (2016) Peiling Tsou et al. CANCER RESEARCH
- Targeting CDK4/6 in patients with cancer
- (2016) Erika Hamilton et al. CANCER TREATMENT REVIEWS
- TMPRSS2-ERG in Blood and Docetaxel Resistance in Metastatic Castration-resistant Prostate Cancer
- (2016) Òscar Reig et al. EUROPEAN UROLOGY
- Biallelic Inactivation of BRCA2 in Platinum-sensitive Metastatic Castration-resistant Prostate Cancer
- (2016) Heather H. Cheng et al. EUROPEAN UROLOGY
- Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
- (2016) Nicholas D James et al. LANCET
- BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate Cancer
- (2016) I. A. Asangani et al. MOLECULAR CANCER RESEARCH
- Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer
- (2016) Himisha Beltran et al. NATURE MEDICINE
- A Phase I/II Study of the Investigational Drug Alisertib in Combination With Abiraterone and Prednisone for Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Abiraterone
- (2016) Jianqing Lin et al. ONCOLOGIST
- Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer
- (2016) Julie N. Graff et al. Oncotarget
- Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer
- (2016) Alexander W. Wyatt et al. JAMA Oncology
- Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer
- (2015) Consuelo Buttigliero et al. CANCER TREATMENT REVIEWS
- Integrative Clinical Genomics of Advanced Prostate Cancer
- (2015) Dan Robinson et al. CELL
- Novel Actions of Next-Generation Taxanes Benefit Advanced Stages of Prostate Cancer
- (2015) R. de Leeuw et al. CLINICAL CANCER RESEARCH
- Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer
- (2015) A. A. Azad et al. CLINICAL CANCER RESEARCH
- Regulation of tumor cell plasticity by the androgen receptor in prostate cancer
- (2015) J. L. Bishop et al. ENDOCRINE-RELATED CANCER
- A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G
- (2015) Edgardo D. Carosella et al. EUROPEAN UROLOGY
- IND 205B: A phase II study of the PI3K inhibitor PX-866 and continued abiraterone/prednisone in patients with recurrent or metastatic castration resistant prostate cancer (CRPC) with PSA progression on abiraterone/prednisone.
- (2015) Sebastien J. Hotte et al. JOURNAL OF CLINICAL ONCOLOGY
- Sequencing of agents in castration-resistant prostate cancer
- (2015) David Lorente et al. LANCET ONCOLOGY
- Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
- (2015) Charles J Ryan et al. LANCET ONCOLOGY
- Switching and withdrawing hormonal agents for castration-resistant prostate cancer
- (2015) David Lorente et al. Nature Reviews Urology
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
- (2015) Christopher J. Sweeney et al. NEW ENGLAND JOURNAL OF MEDICINE
- DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
- (2015) Joaquin Mateo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Temsirolimus Maintenance Therapy After Docetaxel Induction in Castration-Resistant Prostate Cancer
- (2015) U. Emmenegger et al. ONCOLOGIST
- Neoantigens in cancer immunotherapy
- (2015) T. N. Schumacher et al. SCIENCE
- Plasma AR and abiraterone-resistant prostate cancer
- (2015) Alessandro Romanel et al. Science Translational Medicine
- Phase II Trial of Carboplatin, Everolimus, and Prednisone in Metastatic Castration-resistant Prostate Cancer Pretreated With Docetaxel Chemotherapy: A Prostate Cancer Clinical Trial Consortium Study
- (2015) Ulka Vaishampayan et al. UROLOGY
- Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy
- (2015) W. Peng et al. Cancer Discovery
- Inhibition of EZH2 by chemo- and radiotherapy agents and small molecule inhibitors induces cell death in castration-resistant prostate cancer
- (2015) Changping Wu et al. Oncotarget
- Genetic Polymorphism in Extracellular Regulators of Wnt Signaling Pathway
- (2015) Garima Sharma et al. Biomed Research International
- Androgen deprivation therapy sensitizes prostate cancer cells to T-cell killing through androgen receptor dependent modulation of the apoptotic pathway
- (2015) Andressa Ardiani et al. Oncotarget
- PD-L1 is highly expressed in Enzalutamide resistant prostate cancer
- (2015) Jennifer L. Bishop et al. Oncotarget
- Concurrent AURKA and MYCN Gene Amplifications Are Harbingers of Lethal TreatmentRelated Neuroendocrine Prostate Cancer
- (2015) Juan Miguel Mosquera et al. NEOPLASIA
- Risk of Prostate Cancer in Lynch Syndrome: A Systematic Review and Meta-analysis
- (2014) S. Ryan et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- High prevalence of mismatch repair deficiency in prostate cancers diagnosed in mismatch repair gene mutation carriers from the colon cancer family registry
- (2014) Christophe Rosty et al. Familial Cancer
- Conversion of Androgen Receptor Signaling From a Growth Suppressor in Normal Prostate Epithelial Cells to an Oncogene in Prostate Cancer Cells Involves a Gain of Function in c-Myc Regulation
- (2014) Donald J. Vander Griend et al. International Journal of Biological Sciences
- Targeting DNA repair with combination veliparib (ABT-888) and temozolomide in patients with metastatic castration-resistant prostate cancer
- (2014) Maha Hussain et al. INVESTIGATIONAL NEW DRUGS
- Sex steroid blockade enhances thymopoiesis by modulating Notch signaling
- (2014) Enrico Velardi et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Tumor infiltrating B-cells are increased in prostate cancer tissue
- (2014) Jason R Woo et al. Journal of Translational Medicine
- Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer
- (2014) Irfan A. Asangani et al. NATURE
- PI3K and cancer: lessons, challenges and opportunities
- (2014) David A. Fruman et al. NATURE REVIEWS DRUG DISCOVERY
- AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
- (2014) Emmanuel S. Antonarakis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Applying Synthetic Lethality for the Selective Targeting of Cancer
- (2014) Donal P. McLornan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Androgens alter T-cell immunity by inhibiting T-helper 1 differentiation
- (2014) Haydn T. Kissick et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Androgen receptor (AR) suppresses normal human prostate epithelial cell proliferation via AR/β-catenin/TCF-4 complex inhibition ofc-MYCtranscription
- (2014) Lizamma Antony et al. PROSTATE
- Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer
- (2014) Colin C. Pritchard et al. Nature Communications
- Glucocorticoid Receptor Activity Contributes to Resistance to Androgen-Targeted Therapy in Prostate Cancer
- (2014) Masis Isikbay et al. Hormones & Cancer
- A phase II study evaluating the toxicity and efficacy of single-agent temsirolimus in chemotherapy-naïve castration-resistant prostate cancer
- (2013) K Kruczek et al. BRITISH JOURNAL OF CANCER
- Glucocorticoid Receptor Confers Resistance to Antiandrogens by Bypassing Androgen Receptor Blockade
- (2013) Vivek K. Arora et al. CELL
- Punctuated Evolution of Prostate Cancer Genomes
- (2013) Sylvan C. Baca et al. CELL
- Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer
- (2013) A. M. Aparicio et al. CLINICAL CANCER RESEARCH
- Rb Loss Is Characteristic of Prostatic Small Cell Neuroendocrine Carcinoma
- (2013) H.-L. Tan et al. CLINICAL CANCER RESEARCH
- A Phase II Trial of Temsirolimus in Men With Castration-Resistant Metastatic Prostate Cancer
- (2013) Andrew J. Armstrong et al. Clinical Genitourinary Cancer
- Phase 2 Trial of Single-agent Everolimus in Chemotherapy-naive Patients with Castration-resistant Prostate Cancer (SAKK 08/08)
- (2013) Arnoud J. Templeton et al. EUROPEAN UROLOGY
- The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial
- (2013) Shahneen K Sandhu et al. LANCET ONCOLOGY
- Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
- (2013) C. Parker et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Hormone-DNA Repair Circuit Governs the Response to Genotoxic Insult
- (2013) J. F. Goodwin et al. Cancer Discovery
- Phase II trial of RAD001 and bicalutamide for castration-resistant prostate cancer
- (2012) Mari Nakabayashi et al. BJU INTERNATIONAL
- Germline BRCA1 mutations increase prostate cancer risk
- (2012) D Leongamornlert et al. BRITISH JOURNAL OF CANCER
- Increased CD8+ T-cell Function following Castration and Immunization Is Countered by Parallel Expansion of Regulatory T Cells
- (2012) S. Tang et al. CANCER RESEARCH
- Poly-gene fusion transcripts and chromothripsis in prostate cancer
- (2012) Chunxiao Wu et al. GENES CHROMOSOMES & CANCER
- The R-spondin family of proteins: Emerging regulators of WNT signaling
- (2012) Yong-Ri Jin et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
- (2012) Karim Fizazi et al. LANCET ONCOLOGY
- The DNA damage response and cancer therapy
- (2012) Christopher J. Lord et al. NATURE
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
- (2012) Howard I. Scher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inactivation of ATM/ATR DNA Damage Checkpoint Promotes Androgen Induced Chromosomal Instability in Prostate Epithelial Cells
- (2012) Yung-Tuen Chiu et al. PLoS One
- Dual Roles of PARP-1 Promote Cancer Growth and Progression
- (2012) M. J. Schiewer et al. Cancer Discovery
- BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients
- (2011) Z Kote-Jarai et al. BRITISH JOURNAL OF CANCER
- Mechanistic Rationale for Inhibition of Poly(ADP-Ribose) Polymerase in ETS Gene Fusion-Positive Prostate Cancer
- (2011) J. Chad Brenner et al. CANCER CELL
- Intratumoral androgen biosynthesis in prostate cancer pathogenesis and response to therapy
- (2011) Changmeng Cai et al. ENDOCRINE-RELATED CANCER
- TMPRSS2-ERG Status in Circulating Tumor Cells as a Predictive Biomarker of Sensitivity in Castration-Resistant Prostate Cancer Patients Treated With Abiraterone Acetate
- (2011) Daniel C. Danila et al. EUROPEAN UROLOGY
- Targeting MYC dependence in cancer by inhibiting BET bromodomains
- (2011) J. A. Mertz et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Understanding the Lethal Variant of Prostate Cancer: Power of Examining Extremes
- (2011) A. Aparicio et al. Cancer Discovery
- Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of New Drug Targets
- (2011) H. Beltran et al. Cancer Discovery
- Integrative Genomic Profiling of Human Prostate Cancer
- (2010) Barry S. Taylor et al. CANCER CELL
- The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression
- (2010) Ankur Sharma et al. JOURNAL OF CLINICAL INVESTIGATION
- Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant
- (2010) Shihua Sun et al. JOURNAL OF CLINICAL INVESTIGATION
- Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. JOURNAL OF CLINICAL ONCOLOGY
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
- (2010) Johann Sebastian de Bono et al. LANCET
- B-cell-derived lymphotoxin promotes castration-resistant prostate cancer
- (2010) Massimo Ammirante et al. NATURE
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Stabilization of N-Myc Is a Critical Function of Aurora A in Human Neuroblastoma
- (2009) Tobias Otto et al. CANCER CELL
- Characterization of ERG, AR and PTEN Gene Status in Circulating Tumor Cells from Patients with Castration-Resistant Prostate Cancer
- (2009) G. Attard et al. CANCER RESEARCH
- Nuclear Receptor-Induced Chromosomal Proximity and DNA Breaks Underlie Specific Translocations in Cancer
- (2009) Chunru Lin et al. CELL
- Wnt/Fz signaling and the cytoskeleton: potential roles in tumorigenesis
- (2009) Shih-Lei Lai et al. CELL RESEARCH
- Prostate cancer lesions are surrounded by FOXP3+, PD-1+ and B7-H1+ lymphocyte clusters
- (2009) Kathleen Ebelt et al. EUROPEAN JOURNAL OF CANCER
- Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate
- (2009) Brett S Carver et al. NATURE GENETICS
- Induced Chromosomal Proximity and Gene Fusions in Prostate Cancer
- (2009) R.-S. Mani et al. SCIENCE
- Stromal Transforming Growth Factor- Signaling Mediates Prostatic Response to Androgen Ablation by Paracrine Wnt Activity
- (2008) V. R. Placencio et al. CANCER RESEARCH
- Ligand-Independent Androgen Receptor Variants Derived from Splicing of Cryptic Exons Signify Hormone-Refractory Prostate Cancer
- (2008) R. Hu et al. CANCER RESEARCH
- Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 Study
- (2008) Dominik R. Berthold et al. JOURNAL OF CLINICAL ONCOLOGY
- Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis
- (2008) Bora Gurel et al. MODERN PATHOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation